Vinblastine, Bleomycin, and Methotrexate Chemotherapy plus Irradiation for Patients with Early-Stage, Favorable Hodgkin Lymphoma: The Experience of the Gruppo Italiano Studio Linfomi

Paolo G. Gobbi, Chiara Broglia, Francesco Merli, Matteo Dell'Olio, Caterina Stelitano, Emilio Iannitto, Massimo Federico, Raffaella Bertè, Dimitri Luisi, Stefano Molica, Carla Cavalli, Laura Dezza, Edoardo Ascari

Research output: Contribution to journalArticle

Abstract

BACKGROUND. The acknowledged effectiveness of vinblastine, bleomycin, and methotrexate (VBM) chemotherapy in patients with early-stage Hodgkin lymphoma has been associated with conflicting toxicity reports. METHODS. One hundred forty-three patients were evaluated clinically and had favorable Stage IA or IIA Hodgkin lymphoma. Ninety-three patients were treated with the standard VBM schedule combined with extended-field radiotherapy (EF-RT), leaving the choice of the therapeutic sequence free. Fifty subsequent patients were treated with a slightly modified VBM schedule (VbMp) combined with RT limited to involved fields (IF-RT) and delivered only after the end of chemotherapy. In the VbMp schedule, intervals between cycles were 21 days instead of 28 days, bleomycin doses were reduced, small doses of prednisone were given orally, and the interval before RT was prolonged. RESULTS. Clinical response was complete in 96% of patients who were treated with VBM plus EF-RT and in 94% of patients who were treated with VbMp plus IF-RT. Recurrence rates were nearly identical (12% and 11%, respectively) over necessarily different follow-up (91 months and 33 months, respectively). Hematologic toxicity was tolerable in both trials, and pulmonary side effects were moderate in the first trial and negligible in the second. On the whole, treatment was tolerated better when RT followed chemotherapy. CONCLUSIONS. The VBM regimen was confirmed to be effective in patients with early-stage Hodgkin lymphoma. Administration of all cycles before RT improved tolerance; pulmonary toxicity probably is mitigated further by reduced bleomycin doses, mild prednisone therapy, and a more prolonged resting interval before RT A slightly higher recurrence rate was expectable in the VBM plus IF-RT trial despite the actual intensification of vinblastine and methotrexate.

Original languageEnglish
Pages (from-to)2393-2401
Number of pages9
JournalCancer
Volume98
Issue number11
DOIs
Publication statusPublished - Dec 1 2003

Keywords

  • Chemotherapy
  • Hodgkin
  • Radiotherapy
  • Toxicity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Vinblastine, Bleomycin, and Methotrexate Chemotherapy plus Irradiation for Patients with Early-Stage, Favorable Hodgkin Lymphoma: The Experience of the Gruppo Italiano Studio Linfomi'. Together they form a unique fingerprint.

  • Cite this

    Gobbi, P. G., Broglia, C., Merli, F., Dell'Olio, M., Stelitano, C., Iannitto, E., Federico, M., Bertè, R., Luisi, D., Molica, S., Cavalli, C., Dezza, L., & Ascari, E. (2003). Vinblastine, Bleomycin, and Methotrexate Chemotherapy plus Irradiation for Patients with Early-Stage, Favorable Hodgkin Lymphoma: The Experience of the Gruppo Italiano Studio Linfomi. Cancer, 98(11), 2393-2401. https://doi.org/10.1002/cncr.11807